Jill P. Buyon, MD

  • Specialty: Rheumatology
  • Language: English
  • Phone: 646-501-7400

About Me

Conditions and Treatments

sicca syndrome, systemic lupus erythematosus (SLE), rheumatism, lupus erythematosus

Credentials

Positions

  • Professor, Department of Medicine
  • Dir Division of Rheumatology
  • Dir Lupus Center

Board Certifications

    1984
  • American Board of Internal Medicine (Rheumatology)
    1981
  • American Board of Internal Medicine - Internal Medicine

Education and Training

  • 1986
  • Fellowship, Hospital For Joint Diseases, Molecular Biology
  • 1983
  • Fellowship, NYU Medical Center, Rheumatology
  • 1981
  • Residency, Bronx Municipal Hospital Cntr, Internal Medicine
  • 1978
  • MD from Albert Einstein College Of Med

Departments

Locations and Appointments

18 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield Healthy NY
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • HIP Medicaid
  • HealthSmart (WTC)
  • Humana Medicare
  • Medicare
  • UnitedHealthcare Top Tier
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.

NYU Center For Musculoskeletal Care
333 East 38th Street, 4th Floor
New York, NY 10016

Ambulatory Care Services - Lupus Clinic
324 East 23rd Street
New York, NY 10010

Ambulatory Care Services - Osteoporosis Clinic
324 East 23rd Street
New York, NY 10010

Contact

Phone: 212-598-6321

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

Maternal Anti-SSA/Ro-SSB/La Antibodies and Pathogenesis of Congenital Heart Block

Isolated congenital heart block (CHB), detected in utero in a previously normal heart, is strongly associated with autoantibodies that recognize the intracellular soluble ribonucleoproteins 48kD SSB/La, 52kD SSA/Ro, and 60kD SSA/Ro. Neonatal disease is presumed to be due to the transplacental passage of these IgG autoantibodies into the fetal circulation from the mother who may have systemic lupus erythematosus, Sjogren syndrome, or be entirely asymptomatic. However, the role of these antibodies in the direct pathogenesis of cardiac injury is unknown. After characterizing numerous affected neonates and their mothers with respect to health status and antibody profile, we have focused on explaining two major clinical observations: 1) permanent disease does not occur in other fetal organs and the maternal heart is unaffected despite exposure to the identical circulating antibodies; and 2) not all mothers with these antibodies have offspring with disease implying involvement of as yet unknown factors. In addition to these considerations is the overriding question of how intracellular antigens become accessible targets of maternal autoantibodies. We demonstrated that a major antigenic target characterizing the autoimmune response in mothers whose children have manifestations of neonatal lupus is the 52kD Ro protein (52a), which contains an N-terminal zinc finger domain and central leucine zipper. We recently identified an alternative 52mRNA derived from splicing exon 4 inclusive of the leucine zipper, which encodes a smaller protein, 52b, with a predicted molecular weight of 45kD which is immunoprecipitated by over 80% of sera from CHB mothers. Expression of 52b is greatest between 14 and 16 wks of gestation, a time of cardiac ontogeny when maternal antibodies gain access to the fetal circulation just prior to the clinical detection of CHB. Additionally, protein interactions with 52a and 52b are being sought using human adult and fetal (14-24 wk) heart libraries in a two-hybrid system. Human fetal cardiocytes are being cultured to address issues of antigen localization and accessibility to antibody under different conditions. To further the study of neonatal lupus and congenital heart block, we established a national Research Registry for Neonatal Lupus which currently includes 352 affected families.

Publications

  • The clinical spectrum of autoimmune congenital heart block

    Brito-Zeron, Pilar; Izmirly, Peter M; Ramos-Casals, Manuel; Buyon, Jill P; Khamashta, Munther A 2015 Mar; 377-377, Nature reviews. Rheumatology — id: 1513872, year: 2015, page: 377, stat: REVIEW
  • Novel Role of Liver X Receptor Alpha (LXR alpha) in the Attenuation of TLR Signalling: Implications in Congenital Heart Block.

    Bagchi, Susmita; Halushka, Mark; Clancy, Robert M; Buyon, Jill P 2014 OCT; S530-S530, Arthritis & rheumatology — id: 1443992, year: 2014, page: S530
  • Letter to the Editor in response to the article "Preventing congenital neonatal heart block in offspring of mothers with anti-SSA/Ro and SSB/La antibodies: A review of published literature and registered clinical trials." by Gleicher N, Elkayam U, Autoimmun Rev. 2013 Sep;12(11):1039-45

    Costedoat-Chalumeau, Nathalie; Izmirly, Peter; Wahren-Herlenius, Marie; Silverman, Earl; Brucato, Antonio; Boutjdir, Mohamed; Khamashta, Munther; Llanos, Carolina; Pisoni, Cecilia N; Friedman, Deborah M; Clancy, Robert; Phoon, Colin K L; Saxena, Amit; Buyon, Jill P 2014 Jan; 70-72, Autoimmunity reviews — id: 628742, year: 2014, page: 70, stat: Letter
Read All Publications (420)